ReviewEuropean respiratory review : an official journal of the European Respiratory Society2010
Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma.
Review in European respiratory review : an official journal of the European Respiratory Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 259 citations in OpenAlex.
- Role of Leptin as a Link between Asthma and Obesity: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Pooled it
- Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.British journal of clinical pharmacology · 2013Trial
- IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist.The Journal of allergy and clinical immunology · 2012Trial
- The landscape of plasma proteomic links to human organ imaging.Nature communications · 2026Article
- Exacerbations and Management of Asthma in Viral Lower Respiratory Tract Infections: The Significance of Immunoglobulin E.Immunity, inflammation and disease · 2026Review
- Insights on inflammatory pathways and their cross-talk: a comprehensive review on asthma.Molecular biology reports · 2025Review
- Targeting the IL-4/IL-4R Axis in Th2 Inflammatory Diseases: A Review of Clinical Efficacy and Safety.Journal of inflammation research · 2025Review
- A current review on animal models of anti-asthmatic drugs screening.Frontiers in pharmacology · 2025Review
- The role of innate immune system in respiratory viral infection related asthma.Frontiers in cellular and infection microbiology · 2025Review
- Tumor Necrotic Factor-Alpha (-308A/G, rs1800629) and Interleukin-13 (R130Q, rs20541) Gene Polymorphisms as Predictors of Severe Asthma in Pilot Cohort of Kuwaiti Population: Influence of Age, Nasal Polyps, Fractional Exhaled Nitric Oxide, and Blood Eosinophil Count.Journal of asthma and allergy · 2025Article
- Comparative efficacy of biologics for patients with inadequately controlled asthma: A network meta-analysis.The World Allergy Organization journal · 2024Article
- Wnt5a-mediated autophagy contributes to the epithelial-mesenchymal transition of human bronchial epithelial cells during asthma.Molecular medicine (Cambridge, Mass.) · 2024Article
- Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma.Frontiers in pharmacology · 2024Article
- Inflammation plays a critical role in damage to the bronchiolar epithelium induced byInfection and immunity · 2023Article
- IL-13 neutralization attenuates carotid artery intimal hyperplasia and increases endothelial cell migration via modulating the JAK-1/STAT-3 signaling pathway.Cell adhesion & migration · 2023Article
- Gene Therapy for Immunoglobulin E, Complement-Mediated, and Eosinophilic Disorders.Human gene therapy · 2023Review
- Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes.Nature communications · 2023Article
- Exploiting the Macrophage Production of IL-12 in Improvement of Vaccine Development againstVaccines · 2022Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a complex, persistent, inflammatory disease characterised by airway hyperresponsiveness in association with airway inflammation. Studies suggest that regular use of high-dose inhaled corticosteroids and long-acting bronchodilators or omalizumab (a humanised monoclonal antibody that binds to immunoglobulin E and is often used as next-step therapy) may not be sufficient to provide asthma control in all patients, highlighting an important unmet need. Interleukin-4, interleukin-13, and the signal transducer and activator of transcription factor-6 are key components in the development of airway inflammation, mucus production, and airway hyperresponsiveness in asthma. Biological compounds targeting these molecules may provide a new therapeutic modality for patients with uncontrolled severe asthma. The purpose of this review is to summarise current studies of compounds targeting the interleukin-4/interleukin-13 pathway and to provide a rationale for the development of such compounds for this use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.